Results 11 to 20 of about 1,361 (189)

Apremilast Cocrystals with Phenolic Coformers [PDF]

open access: yesMolecules
Apremilast (APR) is an anti-inflammatory drug commonly used in the treatment of psoriasis. In efforts to enhance its solubility, several cocrystals with similar structural features have been developed. This study investigates the cocrystallization of APR
Bohumil Kratochvil   +2 more
exaly   +7 more sources

Screening of coformers for quercetin cocrystals through mechanochemical methods

open access: yesEclética Química, 2022
Quercetin (QUE) is a nutraceutical compound that exhibits pharmacological properties such as antioxidant, cardioprotective, anti-ulcer, and anti-inflammatory effects.
Fayene Zeferino Ribeiro de Souza   +4 more
doaj   +5 more sources

Flavonoid-Based Cocrystals: A Comprehensive Study on Their Synthesis, Characterization, Physicochemical Properties and Applications [PDF]

open access: yesMolecules
Flavonoids are naturally occurring compounds with reported anticancer, antimicrobial, anti-inflammatory, cardio-protective and antioxidant effects. They are increasingly incorporated in functional foods designed to promote health, enhance well-being, and
Urszula Izabela Maciołek   +4 more
doaj   +3 more sources

Carvedilol solubility enhancement by multicomponent crystallization with coformers of benzoic acid, isonicotinamide, and saccharin [PDF]

open access: yesPharmacia, 2023
Multicomponent crystallization is a method that can modify the physicochemical properties of Carvedilol (CVD), thereby increasing its solubility. Based on in silico screening the coformers (Benzoic Acid, Isonicotinamide, and Saccharin) showed non ...
Iyan Sopyan   +3 more
doaj   +4 more sources

Efficient Screening of Coformers for Active Pharmaceutical Ingredient Cocrystallization

open access: yesCrystal Growth & Design, 2022
Controlling the physical properties of solid forms for active pharmaceutical ingredients (APIs) through cocrystallization is an important part of drug product development. However, it is difficult to know a priori which coformers will form cocrystals with a given API, and the current state-of-the-art for cocrystal discovery involves an expensive, time ...
Isaac J. Sugden   +4 more
openaire   +3 more sources

A Review of Coformer Utilization in Multicomponent Crystal Formation

open access: yesMolecules, 2022
Most recently discovered active pharmaceutical molecules and market-approved medicines are poorly soluble in water, resulting in limited drug bioavailability and therapeutic effectiveness.
Nasrul Wathoni   +4 more
doaj   +3 more sources

Among the coformers and cocrystals

open access: yes, 2023
Cocrystals have emerged as an exciting avenue for altering the behavior of drugs and creating new patents or intellectual properties in the pharmaceutical industry. However, the preparation of pharmaceutical cocrystals remains relatively uncommon, presenting a potential field for innovation. The advantage of cocrystals lies in their ability to preserve
Wilson, Ilham Zaky
openaire   +3 more sources

Cocrystals by Design: A Rational Coformer Selection Approach for Tackling the API Problems

open access: yesPharmaceutics, 2023
Active pharmaceutical ingredients (API) with unfavorable physicochemical properties and stability present a significant challenge during their processing into final dosage forms.
Maan Singh   +8 more
doaj   +3 more sources

Cocrystals and Solvates are Not the Same: A Network Perspective. [PDF]

open access: yesChemphyschem
Based on network analysis, cocrystals and solvates cannot be treated the same. Cocrystals and solvates are two kinds of multicomponent crystals. Cocrystals consist of solid compounds, while solvates consist of a mixture of solid and liquid compounds. This work addresses the question of whether cocrystals and solvates can be treated the same or need to ...
de Vries TE   +3 more
europepmc   +2 more sources

Integrative green synthesis and molecular simulation of ibrutinib cocrystals for enhanced biopharmaceutical performance and in vivo pharmacokinetics [PDF]

open access: yesInternational Journal of Pharmaceutics: X
Bruton's tyrosine kinase (BTK) inhibitor, Ibrutinib (IBR), belongs to class II of the Biopharmaceutics Classification System (BCS). CYP3A4 enzyme forces IBR to have a very limited oral bioavailability.
Divya Dhatri Kara   +3 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy